Background and Aims: Digestive adverse events, including nausea and diarrhoea, are the most common adverse effects of nintedanib. When a patient with idiopathic pulmonary fibrosis (IPF) exhibits these adverse effects, nintedanib treatment cannot be continued. However, the clinical features of the development of digestive adverse events during nintedanib administration are unknown. Our aim is to investigate the digestive toxicity of nintedanib and risk factors for development of digestive adverse events following nintedanib administration in patients with IPF.
digestive toxicity of nintedanib and risk factors for development of digestive adverse events following nintedanib administration in patients with IPF.
Methods:
We enrolled 64 Japanese patients with IPF who received nintedanib between October 2015 and April 2018. The diagnosis of IPF was based on the ATS/ERS/JRS/ALAT IPF statement in 2011. We retrospectively evaluated clinical characteristics, including body mass index (BMI); performance status (PS); change in forced vital capacity (FVC); and digestive toxicity, especially nausea and diarrhoea.
Results: The mean FVC was 2192 AE 729 mL before the initiation of nintedanib administration. Moreover, the mean annual decline in FVC was -115 mL. Sixteen and 15 patients developed nausea and diarrhoea of above grade 2 in Common Terminology Criteria for Adverse Events, respectively. Of these patients, half of the patients with nausea and 4 patients with diarrhoea could not receive nintedanib owing to the toxicity. The annual decline in FVC in patients with nausea was significantly lower than that in patients without nausea. To predict the risk of developing nausea and diarrhoea, the optimal BMI cut-off value was calculated as 21.6 kg/m 2 using the receiver operating characteristic curve. Multivariate analysis revealed that poor PS (2-4) and low BMI were significant risk factors for the development of nausea or anorexia due to toxicity of nintedanib. Low BMI trended toward being related to the development of diarrhoea. are not sufficient to use in the clinical settings. It has been reported that soluble IL-2 receptor (sIL-2R) characterized the activation of T cells and was a useful biomarker for several hematologic disorders, autoimmune diseases and sarcoidosis. However, it has not been clarified the clinical significance of sIL-2R in IIP. The goal of this study was to determine whether sIL-2R is a clinically useful biomarker in patients with IIP.
Methods: Review patients with interstitial pneumonia admitted to our hospital, and retrospective analysis was performed. IIP and interstitial pneumonia associated with connective tissue disease (IP-CTD) were included. IIP was also divided into idiopathic pulmonary fibrosis (IPF) and non-IPF according to the recent international consensus classification. Serum sIL-2R was measured and analyzed the relationship with clinical characteristics in patients with interstitial pneumonia.
Results: 191 patients with interstitial pneumonia were included. 118 and 73 patients were IIP and IP-CTD. Serum sIL-2R were significantly higher in patients with IP-CTD compared to those with IIP. In patients with interstitial pneumonia, serum sIL-2R had a significant positive correlation with CRP, ESR and %inflammatory cells in bronchoalveolar lavage fluid, however, a multivariate analysis revealed serum sIL-2R was the prognostic risk factor in patients with IIP, not IP-CTD. In addition, IPF diagnosis was not related to the prognosis in patients with IIP. In patients with IIP, the survival rate was significantly higher in the high serum sIL-2R group compared to the low serum sIL-2R group.
